GlassScriptPhysician profile
Hillary B Gordon
NPI 1851667752
$4,826.98
in general payments reported to CMS, 2019-2025
25 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.43 · 2020: $26.68 · 2022: $29.73 · 2023: $1,011 · 2024: $1,773 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,746 · Education: $2.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,746.32 |
| Education | $2.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $895.98 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $828.79 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Novartis Pharmaceuticals Corporation | $622.16 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $513.37 | 2019-2025 | Dupixent |
| Genzyme Corporation | $372.38 | 2024-2025 | |
| Genentech USA, INC. | $358.68 | 2023-2025 | Xolair |
| Kaleo, INC. | $263.33 | 2020-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $154.42 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $145.50 | 2024-2025 | Cuvitru, Eohilia, Takhzyro |
| Optinose US, INC. | $104.76 | 2023-2025 | |
| Amgen INC. | $99.56 | 2024-2025 | Tezspire |
| Greer Laboratories, INC. | $70.86 | 2024-2025 | Oralair, Palforzia |
| Organon LLC | $56.76 | 2025 | Vtama |
| Csl Behring | $48.50 | 2023-2025 | Andembry, Haegarda |
| Abbvie INC. | $47.63 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $41.12 | 2025 | Xembify |
| Alk-Abello, INC | $40.02 | 2023 | Odactra, Ragwitek, Grastek |
| Blueprint Medicines Corporation | $34.36 | 2023 | Ayvakit |
| Incyte Corporation | $27.10 | 2025 | Opzelura |
| Pfizer INC. | $23.69 | 2024 | |
| Aytu Biopharma, INC. | $20.94 | 2024 | Karbinal |
| Galderma Laboratories, L.P. | $16.64 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $14.74 | 2022 | |
| Merck Sharp & Dohme LLC | $14.01 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.